OSCR
Oscar Health, Inc.
OSCR has the edge over URGN overall, supported by stronger fundamentals and lower modeled downside.
URGN
UroGen Pharma Ltd.
URGN offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
URGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
URGN's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
URGN PE Valuation
URGN has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 15x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
URGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect URGN to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over URGN on earnings quality, reporting a profit while its opponent remains loss making.
URGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.79 | — |
| Q3 2026 | -$1.33 | +$2.13 |
| Q2 2026 | -$1.99 | +$1.33 |
| Q1 2026 | -$2.76 | +$0.42 |
| Q4 2025 | -$3.21 | +$0.02 |
| Q3 2025 | -$3.46 | -$0.13 |
| Q2 2025 | -$3.32 | +$0.14 |
| Q1 2025 | -$3.18 | +$0.40 |
| Q4 2024 | -$3.23 | +$0.68 |
URGN is still losing money, but far less than before: $1.33 per share over the past year, against $6.40 at its worst in late 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over URGN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
URGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $89M | +224% |
| Q2 2026 | $72.5M | +199% |
| Q1 2026 | $51M | +152% |
| Q4 2025 | $37.8M | +54% |
| Q3 2025 | $27.5M | +9% |
| Q2 2025 | $24.2M | +11% |
| Q1 2025 | $20.3M | +7.8% |
| Q4 2024 | $24.6M | +4.4% |
URGN's revenue has grown year over year every quarter since early 2021: $89M last quarter, up 224% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.4% | +109 points |
| Q2 2026 | 0.1% | +171 points |
| Q1 2026 | -40% | +143 points |
| Q4 2025 | -51% | +62 points |
| Q3 2025 | -100% | -30 points |
| Q2 2025 | -171% | -53 points |
| Q1 2025 | -182% | -45 points |
| Q4 2024 | -113% | -51 points |
URGN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over URGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
URGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.3M | +$27.1M |
| Q2 2026 | -$33.1M | +$6.9M |
| Q1 2026 | -$45.4M | -$3.3M |
| Q4 2025 | -$38.3M | -$24.6M |
| Q3 2025 | -$42.4M | -$14.6M |
| Q2 2025 | -$40M | -$16.1M |
| Q1 2025 | -$42.1M | -$10.3M |
| Q4 2024 | -$13.7M | -$682K |
URGN has burned cash in almost every quarter: −$132M over the past year, against −$138M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
URGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +178K shares |
| 1 year | +5.2% | +2.5M shares |
| 3 years | +115% | +27.1M shares |
| 5 years | +126% | +28.2M shares |
| Available history | +146% | +30M shares |
URGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
URGN Net Leverage
URGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
URGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.3 | Neutral |
| Stochastic | 3.5 | Oversold |
URGN's weekly RSI is 36 (neutral) and its Stochastic is 4 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
URGN PE vs Healthcare Sector
URGN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over URGN on trend strength, trading above more of its moving averages.
URGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.1 | 23% below |
| 20 week MA | $39.2 | 33% below |
| 50 week MA | $29.7 | 11% below |
| 100 week MA | $21.9 | 20% above |
| 200 week MA | $17.7 | 49% above |
URGN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 49% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over URGN on returns for 2026, with the stronger performance.
URGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.1 | $18.9 | -43% |
| 2021 | $18.9 | $9.49 | -50% |
| 2022 | $9.49 | $8.14 | -14% |
| 2023 | $8.14 | $15.0 | +84% |
| 2024 | $15.0 | $10.8 | -28% |
| 2025 | $10.8 | $23.0 | +114% |
| 2026 YTD | $23.0 | $26.4 | +15% |
URGN's yearly returns have swung widely, from +114% in 2025 to −50% in 2021. It's up 15% so far in 2026.